more evidence of the bright future for PMN310https://www.researchgate.net/publication/343618119_Aducanumab_gantenerumab_BAN2401_and_ALZ-801-the_first_wave_of_amyloid-targeting_drugs_for_Alzheimer's_disease_with_potential_for_near_term_approval
This peer-reviewed article was published in Aug 2020, and written by a group from Alzheon, a leading AD therapeutic developer.
"The next generation of anti-oligomer therapeutics with improved selectivity and product profiles includes the ollowing agents and mechanisms: (1) PMN310, an anti-amyloid antibody that selectively clears formed Aβoligomers; (2) CT1812, a small molecule that inhibits Aβoligomer binding to specific neuronal receptors thatmediate neurotoxicity; and (3) PQ912 and ALZ-801,small molecules that prevent the formation of neuro-toxic soluble Aβoligomers. An example of an antibodydesigned to be highly selective to Aβoligomers isPMN310 from ProMIS Neuroscience [49], which is inpreclinical development. CT1812 is an oral smallmolecule from Cognition Therapeutics that inhibits thebinding of Aβoligomers to sigma-2 receptors [50],which is thought to mediate some of the oligomer-induced synaptic toxicity. CT1812 is currently beingtested in phase 2 studies. PQ912 is an oral small mol-ecule inhibitor of glutaminyl cyclase from VivoryonTherapeutics that inhibits the formation of pyrogluta-mate forms of Aβoligomers, which are thought to behighly toxic to synapses. In a small phase 2 study of 12-week duration, PQ912 showed promising effects on abiomarker of neuroinflammation in CSF [51].